Phaseline

Companies › Biotheus

Biotheus: clinical trials, targets and expected readouts

1 active drug program in 9 registered trials: 5 Phase 2, 2 Phase 3, 2 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PM8002
bispecific antibody targeting PD-L1 and VEGF
CD274, VEGFA, PDCD1LG2Phase 3SCLC; Triple Negative Breast Cancer(TNBC); NSCLC; Neuroendocrine Neoplasm …Jan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05844150PM8002Phase 2SCLCOncologyMay 2024
NCT05756972PM8002Phase 2NSCLCOncologySep 2024
NCT05879068PM8002Phase 2SCLCOncologyApr 2025
NCT05918445PM8002Phase 1Malignant NeoplasmOncologyNov 2025
NCT05918133PM8002Phase 1TNBCOncologyOct 2026
NCT05879055PM8002Phase 2Neuroendocrine NeoplasmOncologyJan 2027
NCT06616532PM8002Phase 3SCLCOncologyMay 2027
NCT07133750PM8002Phase 2CRC (Colorectal Cancer)OncologyMay 2027
NCT06419621PM8002Phase 3Triple Negative Breast Cancer(TNBC)OncologyJul 2027

Targets

CD274 (1) VEGFA (1) PDCD1LG2 (1)

Companies with the same targets

Roche AstraZeneca Pfizer Akeso Suzhou Suncadia Biopharmaceuticals Shanghai Henlius Biotech Amgen IO Biotech AP Biosciences Jiangsu Simcere Pharmaceutical

Companies built like this

LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company Quercis Pharma ABX advanced biochemical compounds

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.